The flu vaccine works by introducing your immune system to harmless pieces of the influenza virus, triggering your body to build defenses before you encounter the real thing. Within about two weeks of vaccination, your body produces antibodies that can recognize and neutralize the flu virus on contact. Those antibodies are your primary shield, but the full picture involves multiple layers of immune response working together.
What Happens Inside Your Body After Vaccination
When you receive a flu shot, you’re injected with inactivated (killed) viral proteins, primarily a surface protein called hemagglutinin that the flu virus uses to latch onto your cells. Your immune system treats these proteins as a threat, even though they can’t cause infection. Specialized white blood cells called B cells recognize the viral proteins and begin multiplying rapidly, each one fine-tuning its ability to lock onto that specific invader. This process, called clonal expansion, creates a custom-fit army of cells that produce antibodies matched precisely to the flu strains in the vaccine.
At the same time, T cells get involved. Some T cells (CD4+ cells) act as coordinators, helping B cells produce higher-quality antibodies. Others (CD8+ cells) learn to identify and kill cells that have already been infected. Both types contribute to protection. The most important outcome of this whole process is that your body creates memory cells: long-lived B and T cells that “remember” the flu virus. If you’re exposed to a matching strain later in the season, these memory cells kick into gear faster and more forcefully than a first-time encounter would allow.
The Shot vs. the Nasal Spray
The injectable flu vaccine and the nasal spray vaccine stimulate the immune system in meaningfully different ways. The shot uses killed virus and primarily drives a strong antibody response in your bloodstream. It’s especially effective at producing the type of antibodies (IgG) that circulate throughout your body and neutralize the virus if it reaches your bloodstream or deeper tissues.
The nasal spray uses a live but weakened virus that replicates briefly in your upper respiratory tract, mimicking a natural infection without causing illness. Because it sets up in the nose and throat, it triggers a broader immune response: not just blood-based antibodies but also local antibodies (IgA) that coat the lining of your airways, right where the flu virus first lands. The nasal spray also tends to activate a wider range of T cells, including the type that kills infected cells directly. This broader response may offer better cross-protection against flu strains that differ slightly from the ones in the vaccine. However, if you already have strong immunity from prior infections or vaccinations, those existing defenses can actually suppress the weakened virus before it replicates enough to boost your immunity. That’s one reason the nasal spray is approved mainly for children aged 2 to 17, who are less likely to have extensive prior flu exposure.
How Strains Are Chosen Each Year
The flu virus mutates constantly, which is why last year’s vaccine won’t reliably protect you this year. The World Health Organization convenes twice annually, in February for the Northern Hemisphere and September for the Southern Hemisphere, to select the strains that will go into the upcoming season’s vaccine. Their decision draws on global surveillance data, lab analysis of how well current antibodies neutralize emerging strains, structural modeling of viral proteins, and forecasts of which variants are likely to dominate months later.
Current vaccines target three strains: an A/H3N2 virus, an A/H1N1 virus, and a B/Victoria virus. Until recently, vaccines covered four strains (quadrivalent), including a second B lineage, but the WHO dropped it after one B lineage stopped circulating widely. The strain selection process is essentially an educated prediction. When the match is good, the vaccine performs well. When circulating viruses shift unexpectedly between selection and flu season, effectiveness drops. In at least one notable case (the 2019-2020 season), the WHO delayed its recommendation by a month after detecting emerging viruses that didn’t match the initial candidate, ultimately choosing a better-matched strain.
Egg-Based, Cell-Based, and Recombinant Vaccines
Most flu vaccines are still produced by growing the virus in fertilized hen’s eggs, a method used for decades. It works, but it has a quirk: flu viruses can pick up small genetic changes as they adapt to growing in eggs. These “egg-adapted changes” can make the virus in the vaccine slightly different from the one circulating in the real world, potentially reducing how well the resulting antibodies match wild flu strains.
Cell-based vaccines sidestep this problem by growing the virus in mammalian cells (specifically a line of dog kidney cells) instead of eggs. The viruses produced this way tend to more closely resemble the ones actually making people sick. Recombinant vaccines go a step further, skipping the virus entirely. They use genetic engineering to produce the key viral protein directly, without growing any virus at all. Both cell-based and recombinant vaccines are also options for people with egg allergies, since they’re produced without eggs.
Why You Might Feel Lousy for a Day or Two
The sore arm, mild fatigue, low-grade fever, or muscle aches some people experience after a flu shot aren’t signs of infection. They’re side effects of your immune system doing exactly what it’s supposed to do. When your body detects the viral proteins in the vaccine, it releases signaling molecules called cytokines that coordinate the immune response. Those same molecules cause inflammation, which is what produces the achiness and fatigue. Research has confirmed that people who report more side effects also show higher levels of these inflammatory signals in their blood, along with slight increases in body temperature.
These symptoms are typically mild and resolve within a day or two. Importantly, studies have found that the severity of side effects does not predict how strong your antibody response will be. Feeling nothing after your shot doesn’t mean it didn’t work, and feeling crummy doesn’t mean you’ll have better protection.
How Effective the Vaccine Actually Is
Flu vaccine effectiveness varies by year, age group, and how well the vaccine matches circulating strains. For the 2023-2024 season, the CDC measured effectiveness at roughly 56 to 65% for children in outpatient settings, meaning vaccinated kids were more than half as likely to need a doctor’s visit for flu. For adults overall, effectiveness ranged from 35 to 47% in outpatient settings and around 40% against hospitalization. For adults 65 and older, effectiveness was lower, ranging from 31 to 37% depending on the setting.
Those numbers may look modest compared to vaccines for measles or polio, but context matters. Even at 35-40% effectiveness, the vaccine substantially reduces the total number of flu-related hospitalizations and deaths across a population of hundreds of millions. And for older adults, whose immune systems naturally produce a weaker response, specially formulated vaccines can help close the gap. High-dose flu vaccines designed for people 65 and older contain four times the amount of viral protein compared to standard-dose shots, prompting a stronger antibody response. Adjuvanted vaccines, which include an ingredient that amplifies the immune reaction, serve a similar purpose.
How Long Protection Lasts
Protection from the flu vaccine isn’t permanent, and it starts fading within the same season you received it. Antibody levels decline steadily after vaccination, with effectiveness dropping by roughly 6 to 11% per month depending on the flu strain. Protection against A/H3N2 viruses, which tend to cause more severe seasons, wanes fastest. One European analysis found effectiveness against H3N2 dropped to zero by about 111 days post-vaccination. Protection against other strains holds up better: effectiveness against A/H1N1 remained relatively stable at 50-55% throughout the season in one multi-year analysis, and protection against influenza B declined more slowly than H3N2.
Overall, vaccine effectiveness stays above zero for at least five to six months, and estimated protection ranges from 54 to 67% during the first 180 days. Waning also hits some groups harder than others: older adults and young children tend to see steeper declines. This is why timing matters. Getting vaccinated in July or August, when doses first become available, risks losing protection before flu season peaks in January or February. September and October are generally the sweet spot, giving your body time to build antibodies before the season starts while preserving enough protection to last through its tail end.